Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment ...

Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...

A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...

Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.